Expert Committee Supports Celltrion’s Proposed Rituxan Biosimilar

Drug Industry Daily
A A
An FDA advisory committee voted in favor of licensing Celltrion’s drug candidate as a biosimilar for Roche’s blockbuster cancer-fighting Rituxan (rituximab).

To View This Article:

Login

Subscribe To Drug Industry Daily